# HARMONi-3 (NCT05899608)

> Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05899608
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Summit Therapeutics
- Conditions: Non-Small Cell Lung Cancer
- Interventions: Ivonescimab Injection; Pembrolizumab Injection
- Enrollment: 1600
- Primary outcome: Overall Survival (OS)
- Primary outcome: Progression Free Survival (PFS)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 25
- YouTube: 5
- Podcasts: 3

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=harmoni-3-nct05899608

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05899608", "email": "<work email>"}; the inbox owner confirms by the emailed link.